SCHOTT Pharma AG & Co KgaA
XETRA:1SXP

Watchlist Manager
SCHOTT Pharma AG & Co KgaA Logo
SCHOTT Pharma AG & Co KgaA
XETRA:1SXP
Watchlist
Price: 27.66 EUR -2.4% Market Closed
Market Cap: 4.2B EUR
Have any thoughts about
SCHOTT Pharma AG & Co KgaA?
Write Note

Intrinsic Value

The intrinsic value of one 1SXP stock under the Base Case scenario is 34.28 EUR. Compared to the current market price of 27.66 EUR, SCHOTT Pharma AG & Co KgaA is Undervalued by 19%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

1SXP Intrinsic Value
34.28 EUR
Undervaluation 19%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
SCHOTT Pharma AG & Co KgaA

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for 1SXP cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about 1SXP?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about SCHOTT Pharma AG & Co KgaA

Provide an overview of the primary business activities
of SCHOTT Pharma AG & Co KgaA.

What unique competitive advantages
does SCHOTT Pharma AG & Co KgaA hold over its rivals?

What risks and challenges
does SCHOTT Pharma AG & Co KgaA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for SCHOTT Pharma AG & Co KgaA.

Provide P/S
for SCHOTT Pharma AG & Co KgaA.

Provide P/E
for SCHOTT Pharma AG & Co KgaA.

Provide P/OCF
for SCHOTT Pharma AG & Co KgaA.

Provide P/FCFE
for SCHOTT Pharma AG & Co KgaA.

Provide P/B
for SCHOTT Pharma AG & Co KgaA.

Provide EV/S
for SCHOTT Pharma AG & Co KgaA.

Provide EV/GP
for SCHOTT Pharma AG & Co KgaA.

Provide EV/EBITDA
for SCHOTT Pharma AG & Co KgaA.

Provide EV/EBIT
for SCHOTT Pharma AG & Co KgaA.

Provide EV/OCF
for SCHOTT Pharma AG & Co KgaA.

Provide EV/FCFF
for SCHOTT Pharma AG & Co KgaA.

Provide EV/IC
for SCHOTT Pharma AG & Co KgaA.

Show me price targets
for SCHOTT Pharma AG & Co KgaA made by professional analysts.

What are the Revenue projections
for SCHOTT Pharma AG & Co KgaA?

How accurate were the past Revenue estimates
for SCHOTT Pharma AG & Co KgaA?

What are the Net Income projections
for SCHOTT Pharma AG & Co KgaA?

How accurate were the past Net Income estimates
for SCHOTT Pharma AG & Co KgaA?

What are the EPS projections
for SCHOTT Pharma AG & Co KgaA?

How accurate were the past EPS estimates
for SCHOTT Pharma AG & Co KgaA?

What are the EBIT projections
for SCHOTT Pharma AG & Co KgaA?

How accurate were the past EBIT estimates
for SCHOTT Pharma AG & Co KgaA?

Compare the revenue forecasts
for SCHOTT Pharma AG & Co KgaA with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of SCHOTT Pharma AG & Co KgaA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of SCHOTT Pharma AG & Co KgaA against its competitors.

Analyze the profit margins
(gross, operating, and net) of SCHOTT Pharma AG & Co KgaA compared to its peers.

Compare the P/E ratios
of SCHOTT Pharma AG & Co KgaA against its peers.

Discuss the investment returns and shareholder value creation
comparing SCHOTT Pharma AG & Co KgaA with its peers.

Analyze the financial leverage
of SCHOTT Pharma AG & Co KgaA compared to its main competitors.

Show all profitability ratios
for SCHOTT Pharma AG & Co KgaA.

Provide ROE
for SCHOTT Pharma AG & Co KgaA.

Provide ROA
for SCHOTT Pharma AG & Co KgaA.

Provide ROIC
for SCHOTT Pharma AG & Co KgaA.

Provide ROCE
for SCHOTT Pharma AG & Co KgaA.

Provide Gross Margin
for SCHOTT Pharma AG & Co KgaA.

Provide Operating Margin
for SCHOTT Pharma AG & Co KgaA.

Provide Net Margin
for SCHOTT Pharma AG & Co KgaA.

Provide FCF Margin
for SCHOTT Pharma AG & Co KgaA.

Show all solvency ratios
for SCHOTT Pharma AG & Co KgaA.

Provide D/E Ratio
for SCHOTT Pharma AG & Co KgaA.

Provide D/A Ratio
for SCHOTT Pharma AG & Co KgaA.

Provide Interest Coverage Ratio
for SCHOTT Pharma AG & Co KgaA.

Provide Altman Z-Score Ratio
for SCHOTT Pharma AG & Co KgaA.

Provide Quick Ratio
for SCHOTT Pharma AG & Co KgaA.

Provide Current Ratio
for SCHOTT Pharma AG & Co KgaA.

Provide Cash Ratio
for SCHOTT Pharma AG & Co KgaA.

What is the historical Revenue growth
over the last 5 years for SCHOTT Pharma AG & Co KgaA?

What is the historical Net Income growth
over the last 5 years for SCHOTT Pharma AG & Co KgaA?

What is the current Free Cash Flow
of SCHOTT Pharma AG & Co KgaA?

Discuss the annual earnings per share (EPS)
trend over the past five years for SCHOTT Pharma AG & Co KgaA.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Revenue & Expenses Breakdown
SCHOTT Pharma AG & Co KgaA

Balance Sheet Decomposition
SCHOTT Pharma AG & Co KgaA

Current Assets 586m
Cash & Short-Term Investments 29.5m
Receivables 380.5m
Other Current Assets 176m
Non-Current Assets 813.1m
Long-Term Investments 84.9m
PP&E 679.7m
Intangibles 30.6m
Other Non-Current Assets 17.9m
Current Liabilities 415.6m
Accounts Payable 91m
Accrued Liabilities 53m
Other Current Liabilities 271.6m
Non-Current Liabilities 215.9m
Long-Term Debt 81.1m
Other Non-Current Liabilities 134.8m
Efficiency

Earnings Waterfall
SCHOTT Pharma AG & Co KgaA

Revenue
948.6m EUR
Cost of Revenue
-624.4m EUR
Gross Profit
324.2m EUR
Operating Expenses
-154.8m EUR
Operating Income
169.4m EUR
Other Expenses
-19m EUR
Net Income
150.4m EUR

Free Cash Flow Analysis
SCHOTT Pharma AG & Co KgaA

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

1SXP Profitability Score
Profitability Due Diligence

SCHOTT Pharma AG & Co KgaA's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

Positive 3-Year Average ROE
Positive Gross Profit
Positive Operating Income
Positive 3-Year Average ROIC
59/100
Profitability
Score

SCHOTT Pharma AG & Co KgaA's profitability score is 59/100. The higher the profitability score, the more profitable the company is.

1SXP Solvency Score
Solvency Due Diligence

SCHOTT Pharma AG & Co KgaA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

High Interest Coverage
High Altman Z-Score
Low D/E
Long-Term Solvency
78/100
Solvency
Score

SCHOTT Pharma AG & Co KgaA's solvency score is 78/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

1SXP Price Targets Summary
SCHOTT Pharma AG & Co KgaA

Wall Street analysts forecast 1SXP stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for 1SXP is 35.18 EUR with a low forecast of 31.31 EUR and a high forecast of 40.95 EUR.

Lowest
Price Target
31.31 EUR
13% Upside
Average
Price Target
35.18 EUR
27% Upside
Highest
Price Target
40.95 EUR
48% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for 1SXP?

Click here to dive deeper.

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for 1SXP is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

SCHOTT Pharma AG & Co KgaA Logo
SCHOTT Pharma AG & Co KgaA

Country

Germany

Industry

Life Sciences Tools & Services

Market Cap

4.2B EUR

Dividend Yield

0.54%

Description

SCHOTT Pharma AG & Co KgaA is a DE-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Mainz, Hessen. The company went IPO on 2023-09-28. SCHOTT Pharma AG & Co. KGaA is a Germany-based Company, which designs advanced drug containment and drug delivery solutions for the pharmaceutical and biotech industries. The firm's product portfolio ranges from drug containment solutions to drug delivery systems manufactured in collaboration with industry partners. Its selection of pharmaceutical syringes, cartridges, vials, and ampoules is one of the widest and advanced on the market for injectable drugs.

Contact

HESSEN
MAINZ
Hattenbergstrasse 10
+496131660
www.schott-pharma.com

IPO

2023-09-28

Employees

-

Officers

Chairperson of Management Board & CEO of SCHOTT Pharma Management AG
Mr. Andreas Reisse
Chief Financial Officer of SCHOTT Pharma Management AG
Dr. Almuth Steinkuhler

See Also

Discover More
What is the Intrinsic Value of one 1SXP stock?

The intrinsic value of one 1SXP stock under the Base Case scenario is 34.28 EUR.

Is 1SXP stock undervalued or overvalued?

Compared to the current market price of 27.66 EUR, SCHOTT Pharma AG & Co KgaA is Undervalued by 19%.

Back to Top